Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 1931Neoplasms 1385Carcinoma, Non-Small-Cell Lung 1324Prostatic Neoplasms 1070Multiple Myeloma 855Leukemia, Myeloid, Acute 759Neoplasm Metastasis 691Colorectal Neoplasms 676Melanoma 666Lung Neoplasms 665Lymphoma 655Leukemia 591Lymphoma, Non-Hodgkin 587Leukemia, Lymphocytic, Chronic, B-Cell 529Ovarian Neoplasms 517Pancreatic Neoplasms 493Precursor Cell Lymphoblastic Leukemia-Lymphoma 471Recurrence 466Myelodysplastic Syndromes 421Lymphoma, Follicular 407Head and Neck Neoplasms 401Glioblastoma 376Carcinoma, Renal Cell 375Lymphoma, Large B-Cell, Diffuse 372Brain Neoplasms 370Hodgkin Disease 352Carcinoma, Hepatocellular 324Squamous Cell Carcinoma of Head and Neck 323Lymphoma, Mantle-Cell 302Sarcoma 281

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has results × Advanced Ovarian Cancer × Clear all
NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
9 enrolled 11 charts
BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡